NeOnc Technologies Holdings Inc(NTHI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 21 at 4:10 PM ET (Korea 9/22 05:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.12 | Insider Own | 90.35% | Shs Outstand | 24.9M | Perf Week | -11.9% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | 18.71% | Insider Trans | 0.98% | Shs Float | 2.6M | Perf Month | -26.97% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | -0.23 | Inst Own | 10.96% | Short Float | 17.93% | Perf Quarter | -34.83% |
| Income | -0.05B | P/S | - | EPS this Y | 59.7% | Inst Trans | 1.66% | Short Ratio | 2.69 | Perf Half Y | -54.45% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 30.17% | ROA | -1148.42% | Short Interest | 0.47M | Perf YTD | -59.73% |
| Book/sh | -0.75 | P/C | 48.69 | EPS past 3/5Y | -176.88% -109.2% | ROE | - | 52W High | -74.36% ($12.99) | Perf Year | -72.23% |
| Cash/sh | 0.07 | P/FCF | - | Sales past 3/5Y | 25.98% - | ROIC | - | 52W Low | 12.69% ($2.95) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 18.94% | Gross Margin | - | Volatility(W/M) | 15.15% 11.35% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.47 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.14 | EPS Q/Q | -93.43% | Profit Margin | - | RSI (14) | 40.84 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.14 | Sales Q/Q | - | SMA20 | -19.58% ($4.14) | Beta | 1.01 | Target Price | $16 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/10 | SMA50 | -15.17% ($3.93) | Rel Volume | 0.77 | Prev Close | $3.26 |
| Employees | 5 | LT Debt/Eq | - | EPS/Sales Surpr. | -397% - | SMA200 | -47.38% ($6.33) | Avg Volume(3M) | 0.17M | Price | $3.33 |
| IPO | 2025/3/26 | Option/Short | No/Yes | Trades | 1352 | Volume | 135,328 | Change | 2.15% |
Company
NTHI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧠 Neonode Technologies is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including brain tumors. The company focuses on candidates that target the blood-brain barrier, which is notoriously difficult for drugs to cross, and is pursuing novel approaches in hard-to-treat areas such as primary brain cancer. Its valuation is heavily dependent on progress in its clinical pipeline rather than commercialized products.
Over the past 1 year, on the lower side
74% below its 1-year high.
NTHI has weak earning power
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +59.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 11.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $96M.
NTHI $96M PER -
VRTX $129B PER 29.7
REGN $82B PER 19.7
MRNA $69B PER -
FAQ
What kind of company is NTHI?
NTHI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NTHI?
The market cap of NTHI is approximately $96M, ranking 4,577 within its sector.
What is the 52-week high and low for NTHI?
NTHI has recorded a 52-week high of $12.99 and a low of $2.95.
